Related Experiment Video
Updated: Feb 13, 2026

A "Patient-Like" Orthotopic Syngeneic Mouse Model of Hepatocellular Carcinoma Metastasis
Published on: October 24, 2015
Copper/MYC/CTR1 interplay: a dangerous relationship in hepatocellular carcinoma
Cristiana Porcu1,2, Laura Antonucci1,2, Barbara Barbaro1,2
1MESVA Department, University of L'Aquila, L'Aquila, Italy.
Elevated serum copper levels are linked to liver cancer progression. This study reveals how copper, through the MYC/CTR1 pathway, enhances liver cancer cell growth and invasion, offering new diagnostic and therapeutic targets.
Area of Science:
- Hepatocellular Carcinoma Research
- Molecular Biology
- Oncology
Background:
- Serum copper levels correlate with cancer incidence and progression, particularly hepatocellular carcinoma (HCC).
- Non-alcoholic fatty liver disease (NAFLD) progression to HCC is linked to inadequate copper levels.
- MYC oncogene overexpression is common in HCC and drives tumor growth and metastasis.
Purpose of the Study:
- To investigate the role of elevated serum copper in the progression of NAFLD-cirrhosis to HCC.
- To determine if high copper levels sensitize liver cells to transformation.
- To explore the interplay between copper-related proteins and the MYC oncogene.
Main Methods:
- Analysis of serum copper levels in NAFLD-cirrhotic and HCC patients.
- Investigating the effect of high extracellular copper on liver cancer cell growth, migration, and invasion.
- Examining the interaction between MYC and the CTR1 promoter using molecular biology techniques.
Main Results:
- NAFLD-cirrhotic and HCC patients exhibited significantly higher serum copper levels, with the highest in HCC patients.
- High extracellular copper concentrations promoted liver cancer cell growth, migration, and invasion.
- MYC was found to bind the CTR1 promoter, regulating its transcription, with both CTR1 and MYC expression increasing from NAFLD-cirrhosis to HCC.
Conclusions:
- Copper, MYC, and CTR1 form an interplay that promotes liver cancer progression from cirrhosis.
- This Cu/MYC/CTR1 axis offers potential for improved HCC diagnosis and novel combination therapies.
Related Concept Videos
Relationship Formation
Ending Relationships
Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
Relationship Growth
Pharmacokinetic–Pharmacodynamic Relationship: Intensity of Dose-Effect Relationship
Social Relationships and Well-Being

